Seeking Alpha

Onyx Pharmaceuticals (ONXX +4.7%) says that Bayer (BAYRY.PK) has submitted a New Drug...

Onyx Pharmaceuticals (ONXX +4.7%) says that Bayer (BAYRY.PK) has submitted a New Drug Application to the FDA seeking approval for the oral multi-kinase inhibitor regorafenib for the treatment of patients with metastatic colorectal cancer. Regorafenib is a Bayer compound, and Onyx will receive a royalty on global net sales. Separately, Bernstein initiates the shares with an Outperform rating.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs